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Abstract 
We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for 
multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 
patients, median age at allo-HSCT was 51 years (range: 18–78), of whom 4539 (62%) were males. We 
distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) 
allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of 
allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease 
thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around 
year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three 
autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. 
Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-
year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 
32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second 
line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-
HSCT as salvage therapy for MM. 
 
Introduction 
Autologous hematopoietic stem cell transplantation (auto-HSCT) and the development of new 
agents with potent anti-myeloma activity has considerably improved the survival of multiple 
myeloma (MM) patients.
1, 2
 The availability of many of these agents has led to several strategies in 
their use alone or in association either in the induction phase, the consolidation after auto-HSCT, 
  
 
the maintenance phase and the post-relapse phase or at the minimal-residual disease stage.
3, 4, 5, 6, 7, 8
 
However, there is still a continuous risk of relapse mainly due to the inability of these agents to cure 
and eliminate definitively the MM cells. Allogeneic HSCT (allo-HSCT) remains a potentially 
curative treatment but its use is still controversial because of its high morbidity and mortality.
9, 10, 11, 
12, 13, 14
 Conventional myeloablative conditioning (MAC) regimens have given way in the last 
decade to reduced intensity conditioning (RIC) regimen that has been more frequently used in the 
last decade due to significantly reduced transplant-related mortality, which has decreased to 10–
20% but was associated with high relapse rates compared with MAC.
15, 16
 
The most important predictors of outcome are the low-tumor burden at the time of transplant and 
the management of chronic graft-versus-host disease (GvHD) after transplantation.
17, 18
 In this 
regard, the use of auto-HSCT to reduce tumor burden followed by RIC allo-HSCT to obtain a 
benefit from the graft-versus-myeloma effect has been investigated.
19, 20
 A total of six prospective 
randomized trials have compared tandem auto-allo-HSCT versus single/tandem auto-HCT in the 
upfront transplantation setting with conflicting conclusions.
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
 In two 
studies, the auto-allo-HSCT showed an improved progression-free survival (PFS)/event-free 
survival (EFS) and overall survival (OS),
21, 22, 23, 24
 while the rest of the studies failed to prove a 
significant difference in term of PFS/EFS or OS between the auto-HSCT and the auto-allo-HSCT 
strategies. These different results are in part explained by the substantial differences in design, 
patient eligibility, pre-transplantation induction therapy, conditioning regimen, GvHD prophylaxis 
and the important unknown information about treatment at relapse. In view of these uncertainties, 
the debate is still ongoing concerning the best time to propose allogeneic transplantation for patients 
with MM; while there is agreement in the scientific community to perform it preferentially within a 
clinical trial, the use of allo-HSCT for MM in Europe is usually based on individualized decision 
outside of a clinical trial. 
The objective of this study is to describe the use of allo-HSCT for MM in Europe within EBMT 
centers over more than two decades and to evaluate its outcomes. 
Materials and methods 
The EBMT registry 
The EBMT is a non-profit organization that was established in 1974 and maintains a patient 
database known as the EBMT Registry, which encompasses data on HSCT procedures for all 
indications. The EBMT has a centralized database located in Leiden, The Netherlands, where all the 
data requested through the standard data collection forms are stored. The data are submitted when 
100 days have elapsed from the date of transplant, or when the patient dies, whichever comes first. 
All EBMT member centers need to forward these data to retain full membership. All centers must 
obtain informed consent from their patients before the data can be submitted to the EBMT. 
Patient population 
We included patients who received allo-HSCT between 01 January 1990 and 31 December 2012 
and were reported to the EBMT registry. Patients were divided into three groups according to the 
timing of allo-HSCT use—group 1 included patients who received allo-HSCT upfront after 
  
 
induction therapy; group 2 included patients who received allo-HSCT after an upfront single auto-
HSCT as auto-allo tandem transplantation with a maximum interval between auto-HSCT and allo-
HSCT of 8 months; group 3 included patients who received allo-HSCT at a later time after one, two 
or three auto-HSCTs with at least 8 months between the first auto-HSCT and allo-HSCT, mainly as 
second line treatment and beyond. We evaluated the impact of the interval between auto-HSCT and 
allo-HSCT, up to 4 months and between 4 and 8 months. We then merged these patients together as 
their outcomes were similar. Patients with allo-HSCT performed beyond 8 months after auto-HSCT 
could not be considered as receiving tandem auto-allo-HSCT strategy and were therefore included 
in group 3. The three groups were each split into two, that is, including transplants performed 
before and after year 2004, assuming that 2004 was the time of introduction of novel drugs at the 
European centers. 
Statistical analysis 
OS was defined as the time from allogeneic transplantation until date of death or last follow-up. 
PFS was defined as the time from allo-HSCT to disease progression or death from any cause. OS 
and PFS probabilities were estimated by the Kaplan–Meier method, and the Log-Rank test was used 
for univariate comparison. Relapse/progression was defined according to the standard EBMT 
criteria as previously described.
32, 33
 Cumulative incidence of relapse and of death without relapse 
after allo-transplantation (non-relapse mortality (NRM)) was estimated in a competing risks 
framework, and differences were evaluated using the Gray test. 
Results 
 
Patient characteristics 
A total of 7333 patients from 38 different countries received allo-HSCT between 01 January 1990 
and 31 December 2012 and were included in this study. There were 4539 (62%) males and 2794 
(38%) females with a median age at allo-HSCT of 51 years (range: 18–78), of which 4726 (64%) 
have received allo-HSCT after year 2004. Group 1 included 1924 patients, group 2 included 2004 
patients and group 3 included 3405 patients, and among them 514 (27%), 1446 (72%) and 2766 
(81%) received allo-HSCT after year 2004, respectively. Patient characteristics are detailed in Table 
1. 
Table 1. Patient characteristics 
Figures and tables index 
  Allo-HSCT upfront, N=1924 
Tandem auto-allo-HSCT, 
N=2004 
Later allo-HSCT, N=3405 
  
Before year 
2004, N=1410 
After year 
2004, N=514 
Before year 
2004, N=558 
After year 
2004, N=1446 
Before year 
2004, N=639 
After year 
2004, N=2766 
  
 
  Allo-HSCT upfront, N=1924 
Tandem auto-allo-HSCT, 
N=2004 
Later allo-HSCT, N=3405 
  
Before year 
2004, N=1410 
After year 
2004, N=514 
Before year 
2004, N=558 
After year 
2004, N=1446 
Before year 
2004, N=639 
After year 
2004, N=2766 
Median age (range) 46 (18–77) 50 (18 – 78) 51 (21–68) 52 (19 – 72) 52 (27–71) 54 (24 – 73) 
Gender (M/F) 
857 
(61%)/553 
(39%) 
308 
(60%)/207 
(40%) 
339 
(61%)/219 
(39%) 
879 
(61%)/566 
(39%) 
415 
(65%)/224 
(35%) 
1741 
(63%)/1025 
(37%) 
Median time 
diagnosis—allo-HSCT 
(months) 
11 13 11 11 39 39 
              
International Staging System (ISS) 
 I 249 (18%) 48 (9%) 82 (15%) 155 (11%) 105 (16%) 250 (9%) 
 II 30 (2°%) 12 (3%) 12 (2%) 30 (2%) 13 (2%) 32 (1%) 
 III 131 (9%) 36 (7%) 52 (9%) 109 (8%) 42 (7%) 157 (6%) 
 Missing 1000 (71%) 418 (81%) 412 (74%) 1152 (80%) 479 (75%) 2327 (84%) 
              
Durie–Salmon stage 
 I 122 (9%) 28 (5%) 55 (10%) 125 (9%) 54 (8%) 242 (9%) 
 II 206 (15%) 97 (19%) 93 (17%) 229 (16%) 98 (15%) 407 (15%) 
 III 599 (42%) 294 (57%) 340 (61%) 996 (69%) 355 (56%) 1863 (67%) 
 Missing 483 (34%) 95 (18%) 70 (13%) 96 (6%) 132 (21%) 254 (9%) 
              
Disease status at allo-HSCT 
 >PR 191 (14%) 133 (26%) 93 (17%) 421 (29%) 55 (9%) 738 (27%) 
 PR 711 (50%) 243 (47%) 320 (57%) 745 (52%) 268 (42%) 1213 (44%) 
 <PR 366 (26%) 114 (22%) 104 (19%) 188 (13%) 277 (43%) 635 (23%) 
  
 
  Allo-HSCT upfront, N=1924 
Tandem auto-allo-HSCT, 
N=2004 
Later allo-HSCT, N=3405 
  
Before year 
2004, N=1410 
After year 
2004, N=514 
Before year 
2004, N=558 
After year 
2004, N=1446 
Before year 
2004, N=639 
After year 
2004, N=2766 
 Missing 142 (10%) 24 (5%) 41 (7%) 92 (6%) 39 (6%) 160 (6%) 
              
Donor 
 Matched related 1188 (84%) 313 (61%) 449 (80%) 978 (68%) 429 (67%) 1155 (42%) 
 Matched 
unrelated 
121 (9%) 34 (7%) 83 (15%) 126 (9%) 158 (25%) 331 (12%) 
 Other 101 (7%) 167 (32%) 26 (5%) 342 (24%) 52 (8%) 1280 (46%) 
              
Sex matching (R/D) 
 Male/female 330 (23%) 96 (19%) 134 (24%) 318 (22%) 166 (26%) 588 (21%) 
 Others 1080 (77%) 418 (81%) 424 (76%) 1128 (78%) 473 (74%) 2178 (79%) 
              
T-cell depletion 
 Yes/no 
417 
(30%)/993 
(70%) 
137 
(27%)/377 
(73%) 
148 
(27%)/410 
(73%) 
475 
(33%)/971 
(67%) 
202 
(32%)/437 
(68%) 
1254 
(45%)/1512 
(55%) 
              
Stem cells source 
 BM 722 (51%) 78 (15%) 78 (14%) 69 (5%) 110 (17%) 264 (10%) 
 PBSC 688 (49%) 433 (84%) 480 (86%) 1370 (94%) 529 (83%) 2433 (88%) 
 CB — 3 (1%) — 7 (1%) — 69 (2%) 
              
Conditioning 
  
 
  Allo-HSCT upfront, N=1924 
Tandem auto-allo-HSCT, 
N=2004 
Later allo-HSCT, N=3405 
  
Before year 
2004, N=1410 
After year 
2004, N=514 
Before year 
2004, N=558 
After year 
2004, N=1446 
Before year 
2004, N=639 
After year 
2004, N=2766 
 MAC 1046 (74%) 295 (57%) 109 (20%) 278 (19%) 152 (24%) 704 (25%) 
 RIC 215 (15%) 212 (41%) 427 (77%) 1155 (80%) 421 (66%) 2051 (74%) 
 Missing 149 (11%) 7 (2%) 22 (3%) 13 (1%) 66 (10%) 11 (1%) 
              
Number of auto-HSCT before allo-HSCT 
 1 — — 558 (100%) 1446 (100%) 354 (55%) 1237 (45%) 
 2 — — — — 233 (37%) 1285 (46%) 
 3 — — — — 52 (8%) 244 (9%) 
 Abbreviations: BM, bone marrow; CB, cord blood; D, donor; F, female; HSCT, hematopoietic 
stem cell transplantation; M, male; MAC, myeloablative conditioning; PBSC, peripheral blood stem 
cells; PR, partial response; R, recipient; RIC, reduced intensity conditioning. 
 
Trend of allo-HSCT use over time 
The number of allo-HSCTs is continuously increasing to reach its maximum at time of study 
analysis with a total of 612 transplantations performed in 2012. The upfront use of allo-HSCTs 
decreased after year 2000 to represent 12% of allo-HSCTs performed in 2012, while the peak of 
allo-HSCT use directly after one auto-HSCT in a context of tandem auto-allo-HSCTs was around 
year 2004 to reach 19% of usage in 2012. It is clear that allo-HSCT performed at a later time after 
single, double or even three auto-HSCTs, which could be translated in a context of relapse post 
auto-HSCT, was used at the highest rate during the last years to reach 69% of usage in 2012. 
Evolution of allo-HSCT use between years 1990 and 2012 for the different strategies is shown in 
Figure 1. 
 
  
 
 
Interestingly, when taking into consideration the use of allo-HSCTs according to the top 
six countries in Europe, we found that not only the trend of usage is different between 
each country, (that is, increase in Germany compared with others) but also the treatment 
strategy is different between early use versus late use (Figure 2). 
 
  
 
 
 
 Disease and transplantation characteristics 
Baseline disease characteristics are available mainly as disease stage according to Durie–Salmon 
staging. Data were available for 85% of patients and 72% among them were in stage III at the time 
of transplantation (Table 1). Cytogenetic information was missing for the majority of patients with 
data reported only for 483 (6.6%) patients. This lack of data is probably due to the absence of 
routine use of such testing in the past years across centers or it could be missing at the 
transplantation center but available at the referring center. However, since this was outside the 
scope of this descriptive study we did not request those data from the corresponding centers. 
  
 
Response status at transplantation was available for 93% of patients, among them only 24% had a 
response status at transplantation in at least very good partial (VGPR) (Table 1). For conditioning 
regimen, a fast shift was observed around year 2000 from MAC to RIC reaching respective rates of 
34 and 66% of total use in 2012 (Figure 3a). For stem cells source, in 81% of patients, peripheral 
blood stem cells were used while bone marrow was used in 18% of patients and only 1% used cord 
blood. Another shift was also seen in terms of HSC donors, where the usage of HSC from unrelated 
donors have gained over related donors in the recent years with a maximum reached in 2012 
representing 56% versus 44%, respectively (Figure 3b). The use of T-cell depletion in vitro and in 
vivo represented 36% of the total number of performed transplantations. 
  
 
 
  
 
Transplantation outcomes 
At time of analysis, a total of 3140 patients were alive with a median follow-up of 36 months 
(range: 1–270) after date of transplantation. When comparing survival before and after year 2004, 
OS rates have improved after year 2004 with a median OS going from 29 to 40 months in the 
upfront allo-HSCT group (P=0.017); from 63 to 70 months in the tandem auto-allo-HSCT group 
(P=0.11); and from 16 to 26 months in the later allo-HSCT group (P<0.0001) (Figure 4). The 
respective 5-year OS probabilities went from 38% (35–40) before year 2004 to 42% (36–47) after 
year 2004 (P=0.017), from 51% (46–55) to 54% (50–57) (P=0.11) and from 25% (22–29) to 33% 
(30–35) (P<0.0001). When considering only RIC in the tandem auto-allo-HSCT group, the 5-year 
OS according to year of transplant before or after 2004 was 53% and 55% with a median of 74 
months versus 76 months, respectively, (P=0.26). 
  
 
 
Relapse rates were not very different overall after year 2004, with 5-year cumulative incidence 
going from 39 to 38% in the upfront group (P=0.043); from 51 to 47% in the tandem auto-allo-
HSCT group (P=0.12); and from 53 to 55% in the later allo-HSCT group (P=0.59). 
There was a significant improvement in PFS after year 2004 in the auto-allo-HSCT group and the 
later allo-HSCT group, with a median going from 20 to 24 months (P=0.044) and from 7 to 11 
months (P<0.0001) in the two groups, respectively. The PFS difference according to the date cut-
off was not significant in the upfront allo-HSCT group (median going from 14 to 16 months, P= 
0.36). The 5-year PFS probabilities for groups 1, 2 and 3 before and after year 2004 went from 24% 
  
 
(22–27) to 27% (22–32) (P=0.36); from 28% (24–32) to 32% (29–35) (P=0.044); and from 10% 
(8–13) to 15% (13–16) (P<0.0001) respectively (Figure 4). 
NRM improved overall after year 2004 with 3-year cumulative incidence going from 36 to 30% in 
the upfront allo-HSCT group (P=0.014), it was similar in the tandem auto-allo-HSCT group with 
19% (P=0.82) and from 35 to 29% in the later allo-HSCT group (P=0.001). 
Discussion 
Despite the continuous controversy about the use of allogeneic transplantation for treatment of MM, 
the number of patients who received an allogeneic stem cell transplantation in Europe is steadily 
increasing from year 1990 to 2012. A major reason might be that the improvement in outcome with 
novel drugs has yet not translated in cure of the disease and most patients will ultimately relapse. 
Autologous transplantation has improved the outcome, but even when combined with novel drugs 
relapse continues to be the main cause of death. The present study also shows that the timing of 
allogeneic transplantation, as well as the strategy how to perform it varied considerably within the 
European countries. While allo-HSCT is still currently proposed for a good percentage of patients 
in the upfront setting in some countries, other countries have postponed it for a use in second line 
and beyond. The different trends in using allo-HSCT among the European countries might be 
related to the reimbursement by the health authorities and insurance companies, as well as the 
policy of the national myeloma study groups. The descriptive nature of this study gives an idea on 
outcomes for allo-HSCT in the different context of use. Nevertheless, a direct comparison between 
results from different strategies is not possible as there is no adjustment for the different 
characteristics, as well as for the time scale, which was not among our objectives. The actual 
rational of upfront use of allo-HSCT in MM remains in high-risk patients. In this context, 
encouraging results are obtained with the upfront tandem auto-allo-HSCT procedure where 
debulking by a previous autologous transplant appears to maximize the graft-versus-myeloma effect 
by the allogeneic transplant.
17
 The 5-year OS of 55% and a median of 76 months in the tandem 
auto-RIC-allo-HSCT performed after year 2004 are comparable with most trials including auto or 
auto/auto and novel drugs.
34
 However, the most important fact seems to be that long-term survival 
of up to 15 years is obtained in more than 20% of the patients in the auto-allo-HSCT group. Upfront 
allogeneic transplantation, without previous autologous transplantation, is a less advantageous 
approach mainly due to a higher NRM of 34% at 3 years, which is close to the NRM in patients 
transplanted in later stages of the disease. The main reason for this high-NRM upfront is that MAC 
was used in the majority of patients (70 %) while in the tandem modality it was the opposite—79% 
received RIC. The higher NRM with myeloablation translated into poorer OS. However, 
improvement in supportive treatment has reduced NRM even following myeloablative allogeneic 
transplantation in the recent years. 
Although later transplants result in shorter OS than early transplants, the long-term outcome is 
encouraging. Out of the patients who received the transplant >8 month from first auto-HSCT, 
usually in progression or relapse, 25% survived at 10 years from the transplant, some of these 
patients may well be cured. Most of the allo-transplants reported in this study were performed 
before the use of novel drugs. Better results when incorporating second- and third-generation 
proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and histone deacetylase 
inhibitors may well be obtained.
35
 The introduction of these new compounds before and/or after 
transplantation capable of inducing high-response rates with limited side effects has greatly 
  
 
challenged its role, although recent reports have shown that their use and graft-versus-myeloma 
effect are not mutually exclusive and a strong synergistic effect may be established.
36, 37, 38, 39, 40
 In 
our study, the impact of novel drugs could be seen in significant improvement in terms of PFS for 
the auto-allo-HSCT group and the later allo-HSCT group after year 2004. Data concerning 
maintenance therapy after allo-HSCT, including the use of donor lymphocyte infusions in this 
retrospective registry study, especially the reason for their use, were not reliable to evaluate their 
impact on outcomes. Compared with other treatment modalities for MM, allo-HSCT induces a high 
rate of clinical complete response (CR) where at least half of patients with CR also achieve CR at 
the molecular level.
41, 42
 Although remission rates before and after transplantation are important, the 
use of molecular evaluation of minimal-residual disease has been demonstrated to have a highly 
significant impact on disease recurrence detection, where an immediate therapeutic intervention 
could offer a low-risk opportunity to extend the duration of remission and survival.
43, 44, 45
 
Considering the poor outcome for high-risk patients, that is, those with the del(17p), gain(1q), 
t(4;14) and t(14;16) abnormalities, with current treatments, studies of upfront auto-RIC-allo-HSCT, 
including novel drugs, are warranted in such high-risk young patients. Previous prospective and 
retrospective reports evaluating allo-HSCT in MM, in the majority of cases, high-risk patients were 
classified mainly according to beta2 microglobulin and del(13q) that in absence of other poor 
prognostic abnormalities is no longer considered as a high-risk feature.
46
 This prognostic 
classification in addition to differences in design, patient eligibility, pre-transplantation induction 
therapy, conditioning regimen and GvHD prophylaxis may explain the different results between the 
large studies evaluating allo-HSCT in MM and which have substantially impacted on the local 
experience in each country leading to the heterogeneity of allo-HSCT use observed today within 
European countries. In our study, cytogenetic information was missing for the majority of patients 
with data reported only for 6.6% of patients. This lack of data is due to the absence of routine use of 
such testing in the past years across centers or it could be missing at the transplantation center but 
available at the referring center. However, since this was outside the scope of this descriptive study, 
we did not request those data from the corresponding centers. In terms of transplantation settings, 
there was a big shift toward using RIC which also enlarged the use of allo-HSCT for more unfit and 
older patients. There was a remarkable increase in the use of transplants from unrelated donors 
during the last decade. This was supported by encouraging results when optimizing the donor 
selection especially in the human leukocyte antigen settings.
47
 We showed that the majority of allo-
HSCTs performed in the last years were in a context of relapse after one or two autologous 
transplantations. The spectrum of treatment options for patients with relapsed MM had changed 
dramatically after the introduction of novel drugs including the option of using a second auto-
HSCT. However, allo-HSCTs have shown better freedom from disease intervals in these patients.
48, 
49
 Recently, different studies have evaluated the use of novel drugs including panobinostat, 
carfilzomib, elotuzumab and ixazomib, in the context of relapse with very promising results,
50, 51, 52, 
53
 however, a longer follow-up is needed to perform a specific sub analysis regarding those 
combinations and allo-HSCT. The International Myeloma Working Group together with the Blood 
and Marrow Transplant Clinical Trials Network (BMT-CTN), the American Society of Blood and 
Marrow Transplantation (ASBMT) and the European Society of Blood and Marrow Transplantation 
(EBMT) reported consensus on salvage options in patients with relapsed MM.
12
 The authors 
recommended that allogeneic HSCT should be considered as an appropriate therapy for any eligible 
patient with early relapse (<24 months) after primary therapy that included an autologous HSCT 
and/or high-risk features. 
  
 
In conclusion, we showed that the use of allo-HSCT for MM patients is still increasing in Europe 
despite the introduction of novel drugs. The use of allo-HSCT is different between the different 
European countries which reflects the heterogeneous health policies and treatment option 
availabilities, which translates into different local experiences and results. Furthermore, there is a 
clear trend to less perform allo-HSCT at an early stage of the disease (upfront allo-HSCT and 
tandem auto-allo-HSCT), but more in the context of relapsed and/or high-risk patients. While we do 
not give any recommendation for timing of or even any allo-HSCT in myeloma, we want to stress 
out that the increasing use of allo-HSCT after relapse to an autograft needs to be validated in 
prospective comparative studies, which do not exist so far. Despite several consensus and 
recommendations for the use of allo-HSCT in a context of clinical trials, the use of allo-HSCT for 
MM in Europe is actually based on individualized decision outside of a clinical trial. 
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